Can a Dual-Action antibody boost chemo against bile duct cancer?

NCT ID NCT07765433

Not yet recruiting Disease control Sponsor: ECOG-ACRIN Cancer Research Group Source: ClinicalTrials.gov ↗

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This trial is testing whether adding ivonescimab to standard chemotherapy (gemcitabine and cisplatin) works better than the usual chemo-immunotherapy combination for people with advanced biliary tract cancer. Ivonescimab is a special antibody that targets two proteins: one that helps the immune system attack cancer and one that helps tumors grow blood vessels. The study will compare how long patients live and how long the cancer stays under control between the two treatment groups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ivonescimab combined with gemcitabine and cisplatin
What this could lead to: If successful, this could offer a new first-line treatment option that may extend survival for people with advanced biliary tract cancer.
What could go wrong: This is an early-to-mid-stage trial, so results may not confirm benefit. Adding a new drug could also increase side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED BILIARY TRACT ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer cholangiocarcinoma distal biliary tract carcinoma extrahepatic bile duct carcinoma gallbladder adenocarcinoma intrahepatic cholangiocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.